Spectrum of Cardiac Manifestations in COVID-19: A Systematic Echocardiographic Study.


Journal

Circulation
ISSN: 1524-4539
Titre abrégé: Circulation
Pays: United States
ID NLM: 0147763

Informations de publication

Date de publication:
28 07 2020
Historique:
pubmed: 30 5 2020
medline: 12 8 2020
entrez: 30 5 2020
Statut: ppublish

Résumé

Information on the cardiac manifestations of coronavirus disease 2019 (COVID-19) is scarce. We performed a systematic and comprehensive echocardiographic evaluation of consecutive patients hospitalized with COVID-19 infection. One hundred consecutive patients diagnosed with COVID-19 infection underwent complete echocardiographic evaluation within 24 hours of admission and were compared with reference values. Echocardiographic studies included left ventricular (LV) systolic and diastolic function and valve hemodynamics and right ventricular (RV) assessment, as well as lung ultrasound. A second examination was performed in case of clinical deterioration. Thirty-two patients (32%) had a normal echocardiogram at baseline. The most common cardiac pathology was RV dilatation and dysfunction (observed in 39% of patients), followed by LV diastolic dysfunction (16%) and LV systolic dysfunction (10%). Patients with elevated troponin (20%) or worse clinical condition did not demonstrate any significant difference in LV systolic function compared with patients with normal troponin or better clinical condition, but they had worse RV function. Clinical deterioration occurred in 20% of patients. In these patients, the most common echocardiographic abnormality at follow-up was RV function deterioration (12 patients), followed by LV systolic and diastolic deterioration (in 5 patients). Femoral deep vein thrombosis was diagnosed in 5 of 12 patients with RV failure. In COVID-19 infection, LV systolic function is preserved in the majority of patients, but LV diastolic function and RV function are impaired. Elevated troponin and poorer clinical grade are associated with worse RV function. In patients presenting with clinical deterioration at follow-up, acute RV dysfunction, with or without deep vein thrombosis, is more common, but acute LV systolic dysfunction was noted in ≈20%.

Sections du résumé

BACKGROUND
Information on the cardiac manifestations of coronavirus disease 2019 (COVID-19) is scarce. We performed a systematic and comprehensive echocardiographic evaluation of consecutive patients hospitalized with COVID-19 infection.
METHODS
One hundred consecutive patients diagnosed with COVID-19 infection underwent complete echocardiographic evaluation within 24 hours of admission and were compared with reference values. Echocardiographic studies included left ventricular (LV) systolic and diastolic function and valve hemodynamics and right ventricular (RV) assessment, as well as lung ultrasound. A second examination was performed in case of clinical deterioration.
RESULTS
Thirty-two patients (32%) had a normal echocardiogram at baseline. The most common cardiac pathology was RV dilatation and dysfunction (observed in 39% of patients), followed by LV diastolic dysfunction (16%) and LV systolic dysfunction (10%). Patients with elevated troponin (20%) or worse clinical condition did not demonstrate any significant difference in LV systolic function compared with patients with normal troponin or better clinical condition, but they had worse RV function. Clinical deterioration occurred in 20% of patients. In these patients, the most common echocardiographic abnormality at follow-up was RV function deterioration (12 patients), followed by LV systolic and diastolic deterioration (in 5 patients). Femoral deep vein thrombosis was diagnosed in 5 of 12 patients with RV failure.
CONCLUSIONS
In COVID-19 infection, LV systolic function is preserved in the majority of patients, but LV diastolic function and RV function are impaired. Elevated troponin and poorer clinical grade are associated with worse RV function. In patients presenting with clinical deterioration at follow-up, acute RV dysfunction, with or without deep vein thrombosis, is more common, but acute LV systolic dysfunction was noted in ≈20%.

Identifiants

pubmed: 32469253
doi: 10.1161/CIRCULATIONAHA.120.047971
pmc: PMC7382541
doi:

Substances chimiques

Troponin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

342-353

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Références

Eur Heart J. 2020 Mar 16;:
pubmed: 32176300
JAMA Cardiol. 2020 Mar 27;:
pubmed: 32219356
Circulation. 2013 Oct 15;128(16):1810-52
pubmed: 23741057
J Am Soc Echocardiogr. 2016 Apr;29(4):277-314
pubmed: 27037982
Circulation. 1983 Aug;68(2):302-9
pubmed: 6861308
Crit Care. 2019 Nov 27;23(1):374
pubmed: 31775846
J Am Coll Cardiol. 2020 Jun 23;75(24):3078-3084
pubmed: 32272153
J Thromb Haemost. 2020 Jul;18(7):1752-1755
pubmed: 32267998
Circulation. 2003 Oct 14;108(15):1798-803
pubmed: 14504188
Intensive Care Med. 2020 Feb;46(2):357-360
pubmed: 32025779
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
Eur Heart J. 2012 Apr;33(7):895-903
pubmed: 21911341
Circulation. 2011 May 10;123(18):1929-39
pubmed: 21518976
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Anesthesiology. 2015 Feb;122(2):437-47
pubmed: 25501898
Infection. 2020 Apr 10;:
pubmed: 32277408
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
J Thromb Haemost. 2020 May;18(5):1094-1099
pubmed: 32220112

Auteurs

Yishay Szekely (Y)

Tel Aviv Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Israel.

Yael Lichter (Y)

Tel Aviv Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Israel.

Philippe Taieb (P)

Tel Aviv Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Israel.

Ariel Banai (A)

Tel Aviv Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Israel.

Aviram Hochstadt (A)

Tel Aviv Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Israel.

Ilan Merdler (I)

Tel Aviv Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Israel.

Amir Gal Oz (A)

Tel Aviv Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Israel.

Ehud Rothschild (E)

Tel Aviv Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Israel.

Guy Baruch (G)

Tel Aviv Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Israel.

Yogev Peri (Y)

Tel Aviv Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Israel.

Yaron Arbel (Y)

Tel Aviv Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Israel.

Yan Topilsky (Y)

Tel Aviv Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH